NR1I3 and cholestasis: Because hijacking of a CAR regulated mechanism by FXR agonists, represses MRP-4 gene expression and contributes to bile acid-mediated liver injury in cholestasis, its reversal by an FXR antagonist might hold utility in treatment of these disorders [2].